Business Plan


A Sulfur-modified Dependent Restriction Enzyme used in Nucleic Acid Detection

Executive summary

According to the data, the global POCT market scale and growth rate are relatively high, and the geographical distribution of POCT in the world is mainly in developed countries. However, compared with other developed countries, China's POCT market is small, but its growth rate is higher than the global average. At the same time, POCT products for monitoring blood glucose in China account for the largest scale and growth rate of the global POCT testing market. However, China's POCT upstream core raw materials have high barriers, and most of them rely on imports. However, the downstream demand market of the industrial chain continues to expand, and the demand is for more grass-roots people and families. Our business possesses characteristics of having low costs in labor and raw materials, good performance, convenient storage, short production cycle, fast capital demand, cost-effective, sample source is stable outspends ourselves from peer competitors.


Our product is a type of enzyme that is a raw material used in nucleic acid tests. It’s a new technology which can speed up the test a lot than the traditional ways. By applying for patents, we have the ability to establish technical barriers in our country's field of competence, while achieving an advantage in competing with local counterparts. Besides, we have a much lower price and shorter delivery time than other test technique like CRISPR.


The unit price of the product is 120 per 10 microlitre. We decided to promotion and sell our product both online and offline.We plan to reach the break-even point in 3 years and make increased profit in a fast speed. In addition, our product will provide a lot of help in detecting pathogens, which is able to achieve good health and well-being goal and other 3 goals in the Sustainable Development Goals from United Nations.


Market analysis

Global POCT Market Size and Growth Rate got higher

The POCT global market size has been 24.5 billion US dollars since 2019, and the compound growth rate from 2016 to 2019 was 7%. The global compound growth rate of the POCT industry is more than 20%, and the market size is expected to reach 260 billion US dollars in the next two years.

POCT is a sub-industry of in vitro diagnostic products.  Because of its  short detection  time,  infrequent and simple calibration, operability by non-professionals, and high-quality experimental results, it is widely used in hospital ICUs, surgery, emergency, clinics, and patients' homes. It is one of the fastest-growing segments of the IVD industry in recent years. From the global data point of view, POCT growth rate in 2014 was 7.5%, higher than the IVD industry growth rate of 6.5%, and will maintain a compound growth rate of 8%. By 2018, the market is expected to reach $25 billion. According to IQVIA data, from 2017 to 2020, the value of the global POCT market increased from 10.2 billion dollars to 12.3 billion[1]  dollars, an increase of 20.3%. By 2026, the value of the global POCT market will reach 20.4 billion dollars, growing to 1.66 times this year.


Geographical Distribution of the Global POCT mainly in developed countries

POCT Market growth in developing countries will become the main driving force for the expansion of the world market. In view of the large differences in the degree of development, population base, age structure, and medical and health conditions in different regions, the consumption of POCT shows large regional differences. In 2013, the US market reached USD 7.5 billion, accounting for 47%, becoming the world's largest POCT consumption area; the EU market  reached USD 4.87 billion, accounting for 30%,  becoming the second largest  POCT consumption area. In developing countries, with the increasing popularity of the POCT market, the market growth in India, China, and Brazil will become the main driving force for the expansion of the world market.

At the same time, the United States, the country with the largest POCT market development scale, has a market preference for POCT detection for a specific type of disease, and the detection method is biased towards isothermal amplification, or Americans have a wider acceptance of POCT. It can be seen that POCT is highly accepted by American consumers, and the current detection method of isothermal amplification is the most acceptable in the market.

In addition, in developing countries such as China, POCT technology is gradually being accepted by the public. For example, in 2021, China issued the "14th Five-Year Plan" for the development of the medical equipment industry, indicating that POCT is listed as a key development direction. At the same time, the application of constant temperature detection technology is the most extensive, such as nucleic acid detection equipment in recent years.


China POCT Market Size is small but the Growth Rate is high

China accounts for a relatively small proportion of the global POCT market.

The development of POCT has a lot to do with the local economic level, medical conditions, and health awareness. According to statistics, global POCT consumption is mainly concentrated in Europe, the United States and other developed countries and regions, of which the United States has a 34% market share, and Europe accounts for 23%, while China's POCT market only accounts for 5% of the global POCT market. From this point of view, due to the late activation of the Chinese POCT market demand, it will take some time for the Chinese POCT industry to catch up with the developed POCT market in European and American countries.


The annual growth rate of China's POCT industry remains at 20%-30%, higher than the international annual growth rate of 7%-8%. According to the data, it can be concluded that the distribution of listed companies in China's POCT industry tends to be in East and Central China. In 2022, China's total GDP is about 121 trillion yuan, and the total GDP of East China can account for more than 4.6 trillion yuan, accounting for about 40% of China's total GDP. In contrast, the total GDP of central, southern and northern China is between 15 trillion yuan and 16 trillion yuan. Therefore, the ranking of medical levels from high to low is East China, Central China, South China, and North China. And the level of medical care is related to the intensity of economic development. China's POCT market developed late, the current market size is small, but the growth rate is higher than the global level, reaching 22.92% in 2014 and 11 billion yuan in 2021. With the advancement of medical reform and the government's investment in POCT product technology in the construction of primary health care, it is expected that the average annual growth rate will be greater than 20% in the next three years, and the forward-looking forecast is that China's POCT market will rise to about 18 billion yuan in 2027 with CAGR9% from 2022 to 2027.


POCT products for monitoring blood glucose account for the largest size and growth rate of the global POCT testing market.

The future market size will exceed 26 billion yuan. With the advent of an aging society in China, more and more people suffer from chronic patients (diabetes, coronary heart disease, liver and kidney disease). They not only hope to receive systematic diagnosis and treatment from hospitals, but also need POCT technology and instruments that can conduct self-examination, which are simpler and easier to master. Huge business opportunities, huge market demand, high-tech instruments, reagents and technologies have promoted the development of POCT.

On the whole, China's POCT market is still in a relatively early stage of development, and the overall market size and the competitiveness of domestic companies are relatively weak. However, under the medical needs brought by a huge population, China's POCT market has great potential for development.


It is known that the extensive application of our products in POCT can provide testing functions for a variety of epidemic chronic diseases, such as diabetes, which is very serious for Chinese people.


The market size of blood glucose testing products is the largest. Diabetes is also one of the most prevalent chronic diseases. According to statistics, in 2013, the prevalence of diabetes among adults aged 20-79 in the world was 8.3%, and the number of patients had reached a staggering 382 million.  In 2013, a total of 5.1 million people died of diabetes-related diseases worldwide, accounting for 8.39% of all deaths. The global medical cost of diabetes reached 548 billion dollars in that year, accounting for 11% of global medical expenditure. Global healthcare costs related to diabetes are projected to reach $627.3 billion by 2035. In the estimation of the incidence rate and incidence trend of various countries and regions, the number of people with diabetes in China in 2013 was 98.4 million, ranking first in the world, followed by India (65. 1 million), the United States (24.4 million), Brazil (11.9 million), and Russia (10.9 million). Other countries in the top 10 with fewer than 10 million cases include Mexico, Indonesia, Germany, Egypt and Japan. IDF estimates that the number of people with diabetes in China will reach 143 million by 2035, still ranking first in the world. The use of POCT products to monitor blood sugar in real time is currently the main means of preventing and controlling diabetes. Blood glucose detection POCT products include: blood glucose detection system (instrument and reagents), glycated hemoglobin quantitative detection reagents.  Blood glucose detection POCT can allow patients to quickly, conveniently and accurately monitor their blood  glucose levels,  and provide a basis for treatment. The global prevalence of diabetes continues to worsen, and the prevalence of diabetes and the number of diabetic patients are increasing rapidly, making the application of blood glucose detection POCT more and more extensive. According to market research, the global market for blood glucose monitoring POCT products was 4.11 billion dollars in 2011 and is expected to reach 6.43 billion dollars by 2018.


The barriers to core raw materials in the upstream of POCT are relatively high, and most of them rely on imports.

The upstream of the POCT industry chain is mainly the raw material industry, including the biological raw material industry, electronic information industry, and chemical synthesis industry, etc. The upstream of the instrument is mainly the mold and electronic component suppliers, and the upstream of the reagent is mainly fine chemicals, antigens, polymer materials, biological enzymes and other biological raw material suppliers. The downstream demand market mainly includes hospitals, community clinics, health service centers, physical examination centers, etc. These medical institutions account for 90% of the market. Other products, such as blood glucose test strips or blood glucose meters, which are relatively mature in the field of home use, can reach consumers directly through terminal retail such as pharmacies or agents.


The biological raw materials in the upstream raw materials of POCT have a greater impact on the industry. Due to the high technical content of its development field, complex production process, long development cycle, large capital investment, high-quality control requirements, technical mastery and innovation difficulties, the core technology and key raw materials of individual products are still in the hands of several international giants. Therefore, the domestic still cannot achieve independent production of raw materials, almost all core raw materials are dependent on imports. The monopoly on the import of core raw materials makes the domestic bargaining power relatively low, resulting in the high price of domestic POCT products. Although some domestic upstream manufacturers have mastered some technologies through independent research and development, they are still unable to compete with imported products in quality and production scale.


Therefore, we are confident to conclude that POCT upstream raw materials development is difficult and the core technology is difficult to master, so it has been dependent on imports, resulting in high domestic prices. And we have great confidence in the raw materials we produce, our high precision, fast speed, low cost, can effectively improve this phenomenon.


The downstream demand market of the industrial chain continues to expand, promoting localization and familyization

With the development of science and technology and the changes of the times, the downstream demand market of the industrial chain continues to expand, promoting localization and familyization. At present, the clinical departments of hospitals are still the main demand terminal, but with the advancement of hierarchical diagnosis and treatment and the construction of five major treatment centers, the huge grassroots market demand will gradually open up.  In addition, with the deepening of the aging population, the incidence of chronic diseases such as diabetes, chronic kidney disease, tumors, and cardiovascular and cerebrovascular diseases has increased significantly. In addition to in-hospital treatment, chronic diseases still require patients to manage and detect themselves outside the hospital most of the time. This also makes the rigid demand in the home POCT market soar. In addition, the new health concept and medical model of "preventive treatment" have gradually become popular among the people, making the penetration rate, market size and localization substitution of more mature household POCT products such as pregnancy testing and blood sugar testing continue to increase.



low cost*

low price*

concentrated staff*

storage portability*









*Low cost: according to the research, a unit cost below RMB 100 yuan, which stands at 25% lower than the average, is deemed as low cost.

*Low price: according to the research, the price of an item below RMB 168 yuan, which stands at 25% lower than the average, is deemed as low price.

*Concentrated staff: employees are gathered in one place rather than multiple locations, which is easy to manage.

*Storage portability: at minus 20 degrees Celsius, it can be stored for about one and a half years, and more than one and a half years is a longer time.


Porter Five Force

1.  Bargaining power of buyers:

Compared with other raw material manufacturers, our products have high conversion costs, low raw material and labor costs, good economies of scale, mature technology, high-cost performance, mass production, high and stable output. Moreover, our technology has applied for national patents, has intellectual property rights, and can be used for a long time. And in the future, we can become more and more diversified and personalized, with a variety of application scenarios. Therefore, in comparison, if our products have more advantages, the bargaining power of buyers for our products will be relatively low.


2.  Bargaining power of suppliers:

In the future, the production and upgrading of our products will require a large amount of raw materials, so we will purchase raw materials in large quantities for a long time, and the cooperation will be stable, so our bargaining power with our suppliers is high.


3.  Existing competition:

In order to face existing competitors in the POCT raw material industry, we plan to obtain commercial investment as soon as possible, upgrade our existing operations and R&D models, and strive to develop products that better meet customer needs. Most of the investment received will be invested in publicity activities and strive to enter the public eye as soon as possible. Research patents on related technologies have been applied for. In order to cope with the upper limit of technical level, we decided to adopt an elite selection method to inject fresh blood into the team.


4.  Threat of substitute products:

We can also easily respond to threats posed by existing substitute products. This is due to the fact that our products have low raw material and labor costs, short production cycles, fast return on costs, high requirements for quality control, and good performance. Moreover, our products are easy to store, have mature technology and are cost-effective. Therefore, the possibility of product substitution is low and the possibility of profit is high.


5.  Threat of new entrants:

We can also quickly find solutions to future threats from new entrants. We plan to continuously upgrade our existing R&D models and technologies in the future. In the future, we will also try to develop POCT raw materials that can adapt to various environments, and strive to develop products that better meet customer needs.


SWOT Analysis


We have many advantages. First of all, we are mainly concentrated in one place, which means the personnel is relatively gathered, so the efficiency of communication is high and the management cost is reduced. Besides, our products have good performance and convenient storage size, low raw material and labor costs, cost-effectiveness, so it can be mass-produced in the future. Moreover, our R&D pipeline is stable and the investment is within an acceptable range, so the cycle is short and the capital needs are repaid quickly. In addition, our sales staff's professional skills and awareness of maintaining customer relations are relatively good, as we keep in contact with the customers and ask for feedback and suggestions regularly, and the development of potential customers has achieved remarkable results. At the same time, as a supplier, our products have strong compliance and are common in almost all countries. The products are increasingly diversified and personalized, and the application scenarios are diverse. What’s more, the technology has applied for a national patent and has independent intellectual property rights. It also has a close relationship with the government and is led by regional OL in setting industry standards.



On the other hand, we also have some shortcomings, such as insufficient market segmentation, low brand recognition, insufficient inventory, insufficient scale and so on. In addition, because it is a new enterprise, it is temporarily unable to meet the overly personalized product needs of all customers, because we still have the problems of the insufficient product-service model, insufficient product promotion, insufficient user stickiness, insufficient number of sales teams and insufficient funds, and cannot form large customers. However, we will also address issues related to: research and sales of CRO services, sales that do not match different types of customers, and competitive strategies. If we have sufficient funds, we can also effectively solve the difficulties of having a small base of operations, difficult access to local materials, radiation to surrounding customers and lack of advertisement. Although the technical team was successfully formed, due to the small number of personnel, the technical team was not enough to develop too many R&D pipelines, resulting in a slow release of new products.



There are many development opportunities for our products. According to the data as well as the current market situation, the development of POCT in China is slow at present, because POCT has a high raw material cost, long cycle, large capital investment, high-quality control requirements, and difficulties with technology mastery and innovation, which causes the core raw materials mostly rely on imports. In contrast, our product cost is low. Although the capital investment is fast, our capital turnaround cycle is short, which can meet the requirements of most countries. Therefore, we have a first-mover advantage, the market competition pattern is gradually clear, financing success is one’s own liquidity.



At present, we are facing the problem of the sluggish industry environment and weak demand growth. In addition, it is also necessary to face the pressure from international competitors and the malicious subversion of new domestic competitors. Moreover, applying for patents is challenging, and the policies that have been issued carry uncertainties. In addition, we also need to bear the risk of failure of the commercial transformation of the pipeline and the pressure on cash flow in the future.




Strategy Formation


Nature of product

Our product is a type of enzyme as a raw material that can used in all kinds of nucleic acid detection. We provide it in powdery solid as well as liquid, which depends on the needs of clients. For industrial production, the formation of powdery solid is in a large amount (50g in one box, which can produce around 50,000 kits). The product in solid can be packaged and transported at a lower cost and be stored for a longer time. Compared with tablets, powder state is easier to weigh and access in precise amounts. For experiment, liquid is convenient with 10 microliter per cuvette.

The package will be like a square paper box with our logo on it. Each small plastic tube has 50g of solid enzyme inside.


The biosafety transport boxes and logistics vehicles are used in transportation. Because it doesn’t require low temperatures, the cost is low.

The production procedure includes:

1) Add the germ and water into the fermenter.

2) Turn on the fermenter to keep the temperature and mix the things inside. Add the nutrition and hot water into the fermenter continuously.

3) Take out the mixture at the right time.

4) Process it into solid powder as the final product.

The materials required include water, LB, IPTG, incubate at 37 degree C with oxygen. The capital includes the workshop and the fermenters. The rent of workshop is 6000 yuan per square meter per year and one fermenter is 12000 yuan. The whole process takes about 16 hours and is expected to cost 100 yuan every 10 microliters.

The cost center of this procedure is the second step. The fermenters cost a lot on water bill and electricity bill. In order to reduce this cost, we will add the maximum amount into each fermenter every time to use the resource fully and get the output most. Besides, we will write a program to automatically turn all machines off as long as the process finish.

The raw material is another expensive part. We will continue negotiating the price with our supplier to reduce this cost.


Our product uses a completely new technique in China so far. We are the first and the only company which has prepared sulfur modification-dependent restriction enzyme, so we have the patent for it (according to ‘Intellectual Property Protection Law’). This technique can totally replace CRISPR but with no customs and time taken on import, so for domestic companies, they can have the same quality at a much lower cost. We also offer delivery services, which can cut the cost on purchases for these companies.



BTL: For “below the line”, which means promoting the products to specific groups, we will publish articles in magazines like ‘Chinese Medical Journal’ and ‘BMJ’ every season as well as take part in the health summit to introduce our products and spread our business culture. These magazines and summits are highly authoritative and professional. Most people in the medical field check the journals and attend the summits regularly so it’s the fastest way to spread our awareness. Lectures to medical college students will also be held regularly on the topic of microorganisms, bacterium, viruses, and nucleic acid test. This can expand our influence in the long run because these medical students possibly choose our product when they become a doctor. In addition, we can visit the companies in the field of nucleic acid testing or ask specific YouTubers in relevant areas like medicine and biology for advertisement.  


ATL: For “above the line”, which means promoting the products to the public, we can carry out activities in the shopping mall and community for the public to try out our products. Besides, we will cooperate with the hospitals to use our products, in order to achieve the purpose of promotion. In these ways, people can truly feel the advantages of our products like faster speed and more accurate results, and next time they may care about the materials used in nucleic acid tests, which is a kind of force act on our customer companies to choose our material.


-Place: Level1

Our supply chain includes raw material suppliers, enzyme suppliers(our company), POCT or food testing or environment testing companies, customers.

There are four levels in business to describe the process of a product being produced to sell. The zero level only includes the manufacturer and the customer, which means after the product is produced, it will be sold straight to the customer. The first level adds one more part between the manufacturer and the customer, which is the distributor. The extra part in the second level is the retailer, and its sequence is after the distributor. Our product uses Level 1 process because we provide delivery and we have no retailer.




According to the existing microbial detection technologies, the unit price is mainly between 60 to 170 yuan, with an average of 110 yuan. Based on the production costs and analysis of the medical market, our team decided to offer a unit price of 120 yuan per 10 microlitre. Currently, there is no similar technology in China. Sulfur modification-dependent restriction enzyme has a significant difference compared to other POCT methods in the domestic market, which provides advantages in efficiency and cost. Although there is relatively mature technology CRISPR abroad, due to patent restrictions, the cost of use is much higher than others. Therefore, pricing 120 per unit is suitable to attract more customers. In the second year, our team will consider increasing the ways of sale in order to generate more revenue to cover previous research and development costs.



Financial Planning


















Net income(yuan)






Total cost(yuan)






Fixed cost(yuan)






sales and marketing(yuan)


















General and administrative(yuan)






Production cost(yuan)







In the first year, NATWORK will focus on research, development and promotion. In order to produce, it is necessary to purchase quite a large number of production equipment, rent premises, etc.  According to the surveyed data, the annual rent for a standard laboratory is about 6000 per square meter. We plan to have a laboratory size of 20 square meters, totaling approximately 120000 yuan per year. An important production machine Fermentor requires 12,000 yuan. Our team temporarily decided to prepare one Fermentor for production, and most of the other experimental equipment will be provided by the laboratory. Therefore, the equipment cost is expected to be 50,000 yuan.

The team in the first year does not plan to add new members. As the initial R&D team, there are a total of 12 people, each with an annual salary of around 50,000 yuan, totaling around 600,000 yuan. In terms of promotion, we expect to spend up to 30,000 yuan to increase the renown of the new product and attract customers. According to the data provided by the wet lab, it costs approximately 100 yuan per 10 microliter of product, including production costs such as raw materials. In the following years, our team will mainly focus on sales. The cost was mainly consumed in promotion and production. It is expected to reach breakeven in the third year. In the fourth year, we plan to expand our workforce and purchase two additional fermentors to alleviate production pressure. So, there may be an increase in costs this year. In the fifth year, if conditions permit, new research and optimization will be carried out, which will result in another cost expenditure.


Projected timeline

In the first year, NATWORK will focus on completing product research and development, while preparing for future mass production. The team's research and development and production require experimental equipment and venues, which require high costs. We hope to receive investment to support these. In the first year, the entire team consisted of only 12 people, of which 8 were mainly responsible for research and production. In the second half of that year, they will also make their first attempt to sell their products. In terms of publicity, our team will attend some medical exhibitions to let more people get to know our products as well as understand the advantages of using this enzyme.


In the second year, NATWORK will spend more costs on promotion, increasing online and offline sales and marketing. We may go to corresponding companies for promotion as well. As the first year of the product's official launch, with its advantages such as high cost-effectiveness and high efficiency, sales volume will inevitably increase significantly. It is expected to generate a revenue of 7.2 million yuan, which is enough to cover the cost of this year. At this point, profits have just begun, but the cost invested in the first year is relatively high, so our team is still in a loss state.

In the third year, NATWORK expects its product sales to continue to show an increasing trend. Members research the financial reports of some similar companies in the last year. According to the analysis, the outbreak of COVID-19 in 2019-2020 has driven the economic growth of detection reagents by a large margin. And these demand for nucleic acid detection reagents and other related products still exists even if the disease has been gradually controlled later. At the same time, because of COVID-19, we had more knowledge about nucleic acid detection. According to a survey by NATWORK, it is known that people are generally paying more attention to their health status nowadays. In addition, there are frequent outbreaks of influenza in spring and autumn each year, so this demand will be bound to continue increasing in the future. With the development of technology, it may also be applied to more fields. We expect our profit growth rate to reach approximately 40% this year, by stabilizing existing customers and allowing more businesses to see the advantages of our products. At the same time, our team will try to sell the team's products in areas outside of healthcare, like environmental detection and food safety. According to the plan, the estimated income will reach 10,200,000. Under smooth circumstances, we can achieve a balance of income and expenditure this year.


In the fourth year, we will continue to promote sales of our main products and strive to maintain a revenue growth rate of around 30%. The team plans to increase the salaries of veterans and recruit some new personnel while this year. At the same time, purchase two new fermentors to ensure sufficient supply and reduce production pressure.


In the fifth year, based on continuing to sell the first generation of products, utilize a portion of profits to conduct research on upgrading and optimizing previous products, or develop new products.


This is our forecast model:

Forecast model







unit price












unit cost






fixed cost






variable cost






total cost






total revenue












WOGC has listed 17 sustainable development goals to transform our world. Our project has met three of them: Good health and well-being, Clean water and sanitation, and no poverty.


The products developed by NATWORK can be applied to nucleic acid testing, improving detection efficiency and accuracy. The emergence of self-testing kits can make virus detection more convenient, and people can operate them themselves at home. The earlier the cause is detected, the earlier treatment can be received, and in some cases, the probability of cure can also be increased. Therefore, it was able to achieve Good health and well-being.


Although the product is mainly used in the medical field, it can also be applied in other fields such as environmental security. It may help detect pathogens in water and soil to prevent infection. Provided a better living environment for the people, which meets Clean water and sanitation.


These products are even more favorable and have excellent results. than others. At the same time, the use of these products are very easy and can be stored at room temperature, which can save transportation and storage costs. NATWORK has no plans to increase its unit price in current years. This has provided great help and convenience to impoverished areas, meeting the requirements of poverty reduction.


The United Nations Sustainable Development Goals. Image From Wikimedia Commons.


Team  introduction

We are the 2023 iGEM team from Ulink and our name is NATWORK, consisting of 12 members in both wet and dry teams. Our mission is to develop a new material for nucleic acid detection testing - a sulfur-modified dependent restriction enzyme. By studying its binding and cutting mechanisms, we aim to integrate it as an important component into constant temperature detection methods. This will enable instant analysis at the sampling site, eliminating complex processing procedures in the laboratory and allowing for rapid results. In the future, this technology can be widely applied in fields such as molecular medical diagnosis, environmental microbiology detection, food safety, and more.


Dry lab

Gu Yiduo Dora

Dora participated in the design of the offline event, acting as a facilitator and a teaching assistant. Completed two wechat public number of articles written. To Haikou fourth grade students to carry out vitamin science. When writing a business proposal, she and her partner conduct market background research, collect data and analyze it.


Jiang Jue Icy

Icy took charge of the dry lab and communication with the other lab. She editted the promotion video, several PowerPoints and was the speaker in some interview and education activities. In writing the business plan, she took charge of the strategy formation part.


Zhu Xiaozhen Fionn

Fionn participated in the design of online and offline education activities and served as a teaching assistant in those two activities. She also undertook the task of writing and typesetting some Wechat official account articles. At the same time, she also helped to design the two questionnaires and analyze the data of the second one. In the three expert interviews, she served as the meeting recorder, host, and information organizer. She is also responsible for the financial part in the business plan. She is the finance officer of the entire team as well. She has been in charge for purchasing team uniforms and objects used in activities and keeping accounts.


Deng Kaixin Nora

Nora conducted background research and document inquiries for the project, primarily responsible for the formatting and writing of promotional materials on the official account. I  also collaborated with teammates on writing the business proposal and participated in company visits and education activities.


Wet lab

Heng Jingguang Jeff

Jeff participated in the proceedures of most experiments in the lab, including enyzyme digestion, ligation, functional analysis etc. In the mean time, he read through multiple articles about the topic and kept tracking of the daily experiement proceedures and results. Individually, he wrote the results section of our team's wet lab wiki, and designed the animation of the team's promotion video.


Huang Shiyuan Cici

Cici participated most experiment work in lab, including ligation, plasmids transformation, digestion, protein induction and protein purification. Apart from that, she asked and figured out a lot of detailed questions about the molecular mechanisms of the target enzymes. In wikipage job, she was in charge of title, abstract and the body part of engineering (DBTL cycle). As the captain of wet lab, she also communicated with team members and dry lab leader regularly to keep up all procedure.


Wang Xinchun Frisk

Frisk participated in the main parts of the experiments , test and analyze the data and conclude the results. Also a member in the promotion vidso.


Liu Chenchen Erica

Erica participates in extracting plasmid and preparing experiment apparatus.


Qin Lang Amy

Amy participated in most of the experiments in the lab, including plasmid construction, ligation, protein purification etc. In addition, she took part in the conception and the production of the promotion video.


Huang Yixuan Eric

perform Enzyme-cutting and enzyme-linking experiments carry out plasmid construction search for academic papers help make business plan perform Nickel column chromatography demonstrat the specificity of sulfur modification


Liang Chenyu David

David participated in the proceedures of most experiments in the lab, including enyzyme digestion, ligation, functional analysis etc. In the mean time, he read through multiple articles about the topic and kept tracking of the daily experiement proceedures and results. Individually, he wrote the experiment proceedure section and the overview of our engineering success of our team's wet lab wiki, and designed the animation of the team's promotion video.


Cai Yiwei Avery

Avery participated in most of the experiments including enzyme digestion,ligation, protein purification and so forth. She designed the team name and team logo and wrote the meaning of them. She also make a scheme of promotion video. In the wiki, she wrote the results section. She also did some dry lab works including the team introduction in Chinese and English, the English version of questionnaire survey, and the draft of online education.




Tuzi, “Understand the POCT Industry and Clear Up Development Trends”, Zhihu, 2 March 2020. Available at:

According to Tuzi (2020), the POCT industry has had grown by CAGR 18% since 2019 globally.


JinZhichuangxin, “The barrier of core raw materials in the upstream of POCT is high, and domestic products only account for 40% of the market share in China.”, Sohu, 31 July 2019. Available at:

According to JinZhichuangxin (2019), the domestic POCT products only account for 40% of the market share in China.

Hejia, “2022 Global POCT Industry Technology Competitive Landscape”, Forward.The Economist, 4 July 2022. Available at:

According to Hejia (2022), we used some information about the products of Sinocare, Ediagnosis, and GeteinBiotech.

Huayun Li, Yijiang Li, “Medical Device Industry Special Report: COVID-19 Catalyst, POCT Industry Pattern Reshaping”, Hua'an Securities, 27 January 2021. Available at:,%22sourceFrom%22%3A%22search%22%7D

According to Huayun Li and Yijiang Li (2021), the barriers to core raw materials in the upstream of POCT are relatively high, and most of them rely on imports; The downstream demand market of the industrial chain continues to expand.

“Foreseeing 2022: "China POCT Industry Panorama Map in 2022"”, Forward.The Economist, 23 June 2022. Available at:,%22sourceFrom%22%3A%22search%22%7D

According to the Forward.The Economist (2022), the market size of POCT in 2021 was about 11 billion yuan.

Hui Wang, “Efficient Model of Diagnosis in IVD Industry - POCT (III)”, Analytical Testing Encyclopedia Network, 5 July 2021. Available at:

According to Hui Wang (2021), the market size of POCT is expected to maintain an annual compound growth rate of around 8% from 2013 to 2018, and will reach USD 24 billion in 2018.


Dongchuan, “IVD Market Analysis: Nucleic Acid Constant Temperature Amplification”, Little Orange Lantern Net, 2 October 2022. Available at:

According to Dongchuan (2022), the market size of molecular diagnostics in China was about RMB 8.4 billion in 2019, and is expected to reach RMB 27.7 billion by 2024, with a compound annual growth rate of 27.0% from 2019 to 2024.

“Profit Statement of Zhongzhi Bio”, QianZhanYan. Available at: (Accessed: 28 August 2023)

According to QianZhanYan (2023), we gained the financial report of Zhongzhi Biology.

“Profit Statement of Rendu Bio”, Baidu Stock Market Express. Available at:财务 &sheet= 利润分配表 (Accessed: 28 August 2023)

According to Baidu Stock Market Express (2023), we gained the financial report of Rendu Biology.